The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF)

达帕格列嗪 医学 安慰剂 心力衰竭 随机对照试验 可视模拟标度 随机化 内科学 利尿 泌尿科 肾功能 心脏病学 麻醉 内分泌学 糖尿病 替代医学 病理 2型糖尿病
作者
Abdelrahman N. Emara,Moheb Wadie,Noha O. Mansour,Mohamed E. E. Shams
出处
期刊:European Journal of Pharmacology [Elsevier]
卷期号:961: 176179-176179 被引量:2
标识
DOI:10.1016/j.ejphar.2023.176179
摘要

Dapagliflozin may confer additional decongestive and natriuretic benefits to patients with acute heart failure (AHF). Nonetheless, this hypothesis was not clinically examined. This study aimed primarily to investigate the effect of dapagliflozin on symptomatic relief in those patients. This was a randomized, double-blind study that included 87 patients with AHF presenting with dyspnea. Within 24 h of admission, patients were randomized to receive either dapagliflozin (10 mg/day, N = 45) or placebo (N = 42) for 30 days. The primary outcome was the difference between the two groups in the area under the curve (AUC) of visual analogue scale (VAS) dyspnea score over the first 4 days. Secondary endpoints included urinary sodium (Na) after 2 h of randomization, percent change in NT-proBNP, cumulative urine output (UOP), and differences in mortality and hospital readmission rates. The results showed that dapagliflozin significantly reduced the AUC of VAS dyspnea score compared to placebo (3192.2 ± 1631.9 mm × h vs 4713.1 ± 1714.9 mm × h, P < 0.001). The relative change of NT-proBNP compared to its baseline was also larger with dapagliflozin (−34.89% vs −10.085%, P = 0.001). Additionally, higher cumulative UOP was found at day 4 (18600 ml in dapagliflozin vs 13700 in placebo, P = 0.031). Dapagliflozin decreased rehospitalization rates within 30 days after discharge, while it did not affect the spot urinary Na concentration, incidence of worsening of heart failure, or mortality rates. Dapagliflozin may provide symptomatic relief and improve diuresis in patients with AHF. Further studies are needed to confirm these findings. https://clinicaltrials.gov/study/NCT05406505.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
发光诱饵完成签到,获得积分10
2秒前
JamesPei应助kunyi采纳,获得30
2秒前
酷酷羊发布了新的文献求助10
2秒前
2秒前
爆米花应助无辜不言采纳,获得10
2秒前
madison发布了新的文献求助10
3秒前
所所应助后陡门爱神采纳,获得10
3秒前
3秒前
3秒前
3秒前
4秒前
NexusExplorer应助派大星采纳,获得10
4秒前
wuJlin发布了新的文献求助10
4秒前
4秒前
WW完成签到 ,获得积分10
4秒前
曾无忧发布了新的文献求助10
5秒前
安安发布了新的文献求助10
6秒前
6秒前
狂野含巧完成签到 ,获得积分10
7秒前
7秒前
上官若男应助chshqin2采纳,获得10
7秒前
小椰_1733完成签到,获得积分10
7秒前
斯文谷秋发布了新的文献求助10
7秒前
8秒前
8秒前
8秒前
Reef发布了新的文献求助10
8秒前
9秒前
舒适的鱼鱼完成签到,获得积分10
9秒前
Devil完成签到,获得积分10
9秒前
9秒前
9秒前
9秒前
11秒前
小王子发布了新的文献求助10
11秒前
自然紫山发布了新的文献求助10
12秒前
orixero应助哈哈同学采纳,获得10
12秒前
lx完成签到,获得积分10
13秒前
情怀应助田所浩二采纳,获得10
14秒前
14秒前
高分求助中
Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms 2000
Evolution 1500
How to Create Beauty: De Lairesse on the Theory and Practice of Making Art 1000
Gerard de Lairesse : an artist between stage and studio 670
CLSI EP47 Evaluation of Reagent Carryover Effects on Test Results, 1st Edition 550
Multiscale Thermo-Hydro-Mechanics of Frozen Soil: Numerical Frameworks and Constitutive Models 500
Sport, Music, Identities 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 2987214
求助须知:如何正确求助?哪些是违规求助? 2648343
关于积分的说明 7154642
捐赠科研通 2282162
什么是DOI,文献DOI怎么找? 1210168
版权声明 592429
科研通“疑难数据库(出版商)”最低求助积分说明 591004